Second Drug for Benign Synovial Tumor Condition Wins FDA Approval
MedPage Today) — The FDA approved the small-molecule inhibitor vimseltinib (Romvimza) for adults with symptomatic tenosynovial giant cell tumor (TGCT), a rare, non-malignant, but debilitating, condition arising in the synovium, the agency announced…
MedPage Today) — The FDA approved the small-molecule inhibitor vimseltinib (Romvimza) for adults with symptomatic tenosynovial giant cell tumor (TGCT), a rare, non-malignant, but debilitating, condition arising in the synovium, the agency announced…
Read More
About Author
